Literature DB >> 35092672

Reply to Ito and Ogawa.

Patrick Mazi1, Andrej Spec1.   

Abstract

Entities:  

Year:  2022        PMID： 35092672      PMCID： PMC9427143          DOI： 10.1093/cid/ciac067

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   20.999


× No keyword cloud information.
  7 in total

1.  Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome.

Authors:  L J Wheat; P Connolly; M Smedema; E Brizendine; R Hafner
Journal:  Clin Infect Dis       Date:  2001-10-23       Impact factor: 9.079

2.  Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group.

Authors:  J Wheat; S MaWhinney; R Hafner; D McKinsey; D Chen; A Korzun; K J Shakan; P Johnson; R Hamill; D Bamberger; P Pappas; J Stansell; S Koletar; K Squires; R A Larsen; T Cheung; N Hyslop; K K Lai; D Schneider; C Kauffman; M Saag; W Dismukes; W Powderly
Journal:  Am J Med       Date:  1997-09       Impact factor: 4.965

3.  Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole.

Authors:  L Joseph Wheat; Patricia Connolly; Melinda Smedema; Michelle Durkin; Edward Brizendine; Paul Mann; Reena Patel; Paul M McNicholas; Mitchell Goldman
Journal:  J Antimicrob Chemother       Date:  2006-04-20       Impact factor: 5.790

4.  In vitro activity of isavuconazole against fluconazole-resistant isolates of Histoplasma capsulatum.

Authors:  Andrej Spec; Patricia Connolly; Rocio Montejano; L Joseph Wheat
Journal:  Med Mycol       Date:  2018-10-01       Impact factor: 4.076

5.  Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America.

Authors:  L Joseph Wheat; Alison G Freifeld; Martin B Kleiman; John W Baddley; David S McKinsey; James E Loyd; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2007-08-27       Impact factor: 9.079

6.  Voriconazole Versus Itraconazole for the Initial and Step-down Treatment of Histoplasmosis: A Retrospective Cohort.

Authors:  Michael Joshua Hendrix; Lindsey Larson; Adriana M Rauseo; Sasinuch Rutjanawech; Alexander D Franklin; William G Powderly; Andrej Spec
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

7.  A comparison of presentations and outcomes of histoplasmosis across patients with varying immune status.

Authors:  Alexander D Franklin; Lindsey Larson; Adriana M Rauseo; Sasinuch Rutjanawech; Michael Joshua Hendrix; William G Powderly; Andrej Spec
Journal:  Med Mycol       Date:  2021-01-13       Impact factor: 4.076
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.